Gilead Reports Phase 3 Data for Axicabtagene ciloleucel in Thyroid disease

Gilead today announced Phase 3 results for axicabtagene ciloleucel in patients with thyroid disease. The study demonstrated that axicabtagene ciloleucel achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of thyroid disease and support the continued development of axicabtagene ciloleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.